Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEMULEN 1/35-28 vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Ethinylestradiol undergoes hepatic metabolism via CYP3A4; norethindrone undergoes reduction and conjugation in the liver.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 93% bound to albumin and SHBG.
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
Ethinyl estradiol: 2.3-4.3 L/kg; norethindrone: 4.4 L/kg; indicates extensive tissue distribution.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Ethinyl estradiol: 40-45% (oral; first-pass metabolism); norethindrone: 64-67% (oral).
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Avoid use if liver function tests are abnormal.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults (one tablet orally once daily).
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Not indicated for use in postmenopausal women.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and smoking intensity. Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Cerebrovascular disease,Myocardial infarction,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Headache,Uterine bleeding,Ocular lesions,Depression
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Known or suspected pregnancy,Current or past thrombosis,Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenomas or carcinomas,Active liver disease,Known hypersensitivity to any component
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
No significant food interactions. Grapefruit juice has minimal effect on ethinyl estradiol; no restriction needed. Avoid excessive alcohol, which may impair adherence or increase liver enzymes. St. John's wort reduces contraceptive efficacy and should be avoided.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromegaly, labial fusion) due to progestin component; possible association with hypospadias in males with first-trimester exposure. Avoid use in pregnancy.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Excreted in breast milk; estimated infant dose <1% of maternal dose. M/P ratio not available for ethinyl estradiol/ethynodiol diacetate. May reduce milk production and quality. Use only if benefits outweigh risks; lowest effective dose recommended.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Contraindicated in pregnancy; no dose adjustment applicable. If inadvertently used, discontinue immediately.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
DEMULEN 1/35-28 (ethinyl estradiol 35 mcg + ethynodiol diacetate 1 mg) is a monophasic combined oral contraceptive. Its progestin has mild androgenic activity, which may be less favorable for acne-prone patients compared to third-generation pills. The 28-day pack includes 21 active pills and 7 inert pills. Counsel patients to take at the same time daily; missed pills increase breakthrough bleeding and pregnancy risk. It may be used off-label for cycle control in patients without contraindications.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take one pill daily at the same time, preferably after dinner to reduce nausea.,If you miss one pill, take it as soon as remembered; if missed more than one, use backup contraception for 7 days.,Smoking increases risk of blood clots; especially dangerous if over 35 and smokes.,Some antibiotics (e.g., rifampin) and antiseizure medications may reduce effectiveness.,Report any signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Breakthrough bleeding is common in first 3 cycles; if persistent, contact your healthcare provider.,Do not use if pregnant; if pregnancy occurs, stop immediately.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEMULEN 1/35-28 vs DESOGEN, answered by our medical review team.
DEMULEN 1/35-28 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEMULEN 1/35-28 and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEMULEN 1/35-28 is: One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEMULEN 1/35-28 and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEMULEN 1/35-28 is classified as Category C. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromeg. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.